In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Acadia Pharmaceuticals' current price of $19.12 lies below the PERT-weighted fair value of $24.17, indicating a 26.4% implied upside with high confidence. Valuation discrepancies exist, notably a highly negative DCF versus strong P/E and analyst target estimates, suggesting divergent growth/profitability expectations. Financial health scores are excellent, and Monte Carlo analysis shows negligible downside risk, highlighting potential reward with limited downside.